Pneumococcal vaccines and long-term protection
Grant award · Australia · Last reported Dec 2018
Source: GrantConnect
Pneumococcal disease is a major killer of children under 5 years of age, particularly in low- and middle-income countries. Pneumococcal conjugate vaccines (PCVs) are highly effective but costly, and so schedules with fewer PCV doses are being considered. However, the type of immune response that predicts long-term protection following fewer PCV doses is unknown. This information will provide evide
- Status
- Prospective
- Sector
- Hospital, Government
- Location
- Australia
- Updated
- 19 Nov 2026
- Source
- GrantConnect
ConstructChat
Ask ConstructChat about Pneumococcal vaccines and long-term protection
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | grant award |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Pneumococcal disease is a major killer of children under 5 years of age, particularly in low- and middle-income countries. Pneumococcal conjugate vaccines (PCVs) are highly effective but costly, and so schedules with fewer PCV doses are being considered. However, the type of immune response that predicts long-term protection following fewer PCV doses is unknown. This information will provide evidence to support more efficient PCV use in all regions of the world. |
Original sector | Medical Research |
Budget |
Location
Country | Australia |
Source
Source | GrantConnect |
URL |
More Details
Record type | Project |
Sector | Hospital, Government |
Article published date | 2024-12-16 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
